CR Likelihood ?, page-3

There is enough cash to make payment of the next (third) tranche. The fourth and fifth tranches will require more capital. As the project de-risks through meeting the milestones, the payments get larger, because the project is worth more.

The payments don't go to the owners of Wavefront Biometric Technologies, they go into product development.

In the next couple of weeks we should hopefully see a successful review by NXR of the miniaturised corneal scanner, for use in mobile devices, and payment of the third tranche of $675,000 to take equity in WBT from 20% to 30%.

Before raising money for the last two tranches, I expect we will see marketing of the technology to brokers and institutions in order to raise the share price over 5c (hence lowering cost of equity / dilution). Perhaps it's time to show the product to banks and payment providers too.

That's how I think things will pan out from here, if things go well. Always a risk they don't. Who knows, but looks ok IMO.